Headlines



Quartr
PharmaEssentia: ROPEG expands across MPNs as 9M 2026 revenue reaches NTD 19.7B
Quartr
PharmaEssentia: Revenue doubled YoY as operating income rose 168%
TradingView
PharmaEssentia Corporation Reports Preclinical Data on Two Solid-Tumor Programs
Quartr
PharmaEssentia: Q2 2026 revenue rose 90% YoY, net income jumped 204%, and EPS hit a record NT$6.13
Quartr
PharmaEssentia: H1 2026 saw robust revenue and profit growth, major acquisition, and ongoing legal disputes
Reuters
Pharmaessentia Says Jan-Jun Net Profit T$4.68 Bln
Reuters
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi Proceedings
Quartr
PharmaEssentia: Q1 2026 saw robust revenue and profit growth, with global expansion and R&D investments ongoing
Reuters
Pharmaessentia Says To Buy 100% Forus Therapeutics For C$50 Mln
Reuters
Pharmaessentia Signs Agreement For New Manufacturing Facility In Puerto Rico
Quartr
PharmaEssentia: 2025 saw record revenue and profit, robust U.S. growth, and major expansion investments
Reuters
Pharmaessentia Announces Japan Approval Of High-Dose Dosing Regimen For Besremi
Reuters
Pharmaessentia Invests $46 Million In Puerto Rico Subsidiary
Reuters
Pharmaessentia To Invest $46 Million To Set Up Unit In Puerto Rico, U.S. Territory
Reuters
Pharmaessentia Announces Positive Topline Phase 2B Data From Exceed-Et Study Evaluating Ropeginterferon Alfa-2B-Njft For Essential Thrombocythemia
Reuters
PharmaEssentia to Present 2026 Priorities at JPM Conference
Quartr
PharmaEssentia: Net income surged 106% year-over-year on strong sales, with major investments in cell therapy and manufacturing
Quartr
PharmaEssentia: H1 2025 saw revenue and net income surge, with strong cash reserves and key legal disputes resolved
Quartr
PharmaEssentia: Q1 2025 delivered record revenue and profit growth, with robust cash flow and global expansion
Quartr
PharmaEssentia: Returned to profitability with record revenue, strong US sales, and major R&D and capital investments